Skip to main content
Article thumbnail
Location of Repository

Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study

By Markus Ketteler, Kevin J. Martin, Mario Cozzolino, David Goldsmith, Amit Sharma, Samina Khan, Emily Dumas, Michael Amdahl, Steven Marx and Paul Audhya


Background. Paricalcitol and cinacalcet are common therapies for patients on haemodialysis with secondary hyperparathyroidism (SHPT). We conducted a multi-centre study in 12 countries to compare the safety and efficacy of paricalcitol and cinacalcet for the treatment of SHPT

Topics: Original Articles
Publisher: Oxford University Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1998). 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. JA m Soc Nephrol
  2. (2005). Activated injectable vitamin D and hemodialysis survival: a historical cohort study.
  3. (2010). Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. Hemodial Int
  4. (2009). Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients.
  5. (2010). Autocrine/paracrine action of vitamin D on FGF23 expression in cultured rat osteoblasts. Calcif Tissue Int
  6. (2011). Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int
  7. (2010). Capsules [Prescribing Information]. North Chicago, IL: Abbott Laboratories;
  8. (2008). Cinacalcet HCl and concurrent low-dosevitaminD improvestreatment ofsecondaryhyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
  9. (2010). Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int
  10. (2004). Cinacalcetfor secondary hyperparathyroidism in patients receiving hemodialysis.
  11. (2009). Clinical outcomes with active versus nutritional vitamin D compounds in chronickidney disease.
  12. (2008). Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant
  13. (2010). CozzolinoM,KettelerM,ZehnderD.ThevitaminDsystem:acrosstalk between the heart and kidney.
  14. (2010). Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int
  15. (2010). Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients.
  16. (2007). Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism.
  17. (2010). Effects of cinacalcet and concurrent low-dose vitamin
  18. (2009). Factors affecting the quality of life of haemodialysis patients from Romania: a multicentric study. Nephrol Dial Transplant
  19. (2007). Factors associated with health-related quality of life among hemodialysis patients in the DOPPS. Qual Life Res
  20. (2010). FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant
  21. (2010). FGF-23: more than a regulator of renal phosphate handling? J Bone Miner Res
  22. (2008). Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.
  23. (2003). Foundation/KDOQI. KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease.
  24. (2003). Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int
  25. (2004). Health-relatedquality of life in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
  26. (1948). Improving Global Outcomes. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; 76 (Suppl 113): S1–S130
  27. (2004). LazarusJMet al.Mineral metabolism,mortality, and morbidity in maintenance hemodialysis.
  28. (2009). LooCY et al.Intravenouscalcitriolversus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism. Nephrology (Carlton)
  29. (2007). Metabolic bone disease in chronic kidney disease.
  30. (2006). Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int
  31. (2008). Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
  32. (2007). Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
  33. (2010). Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int
  34. (2003). Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int
  35. (2009). Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation
  36. (2007). Rapid identification of emerging infectious agents using PCR and electrospray ionization mass spectrometry.
  37. (2008). Ratio of paricalcitol dosage toserum parathyroid hormonelevel and survivalin maintenance hemodialysis patients.
  38. (2008). Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.
  39. (2003). Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.
  40. (2006). Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int
  41. (2010). Tablets [Prescribing Information]. Thousand Oaks, CA: Amgen Inc;
  42. (2005). The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism.
  43. (2008). The OPTIMAstudy: assessinga new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
  44. (2009). Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.
  45. (2010). Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis.
  46. (2007). VitaminDlevelsandearlymortality among incident hemodialysis patients. Kidney Int
  47. (2009). Zemplar (Paricalcitol Injection) Injection, Solution [Prescribing Information]. North Chicago, IL: Abbott Laboratories;

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.